<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078503</url>
  </required_header>
  <id_info>
    <org_study_id>NP3468</org_study_id>
    <nct_id>NCT04078503</nct_id>
  </id_info>
  <brief_title>Neuroinflammation During ICU-associated Delirium in Critically Ill Patients and Its Association With Structural and Functional Brain Alterations: a Nested Case-control Study</brief_title>
  <acronym>Delirium-fMRI</acronym>
  <official_title>Neuroinflammation During ICU-associated Delirium in Critically Ill Patients and Its Association With Structural and Functional Brain Alterations: a Nested Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pisa, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the present study, the authors aim to improve the knowledge of the pathophysiology of
      ICU-related delirium. In particular, the authors would like to clarify the possible
      correlation between neuroinflammation, evaluated longitudinally by serum dosage of 20
      different neuroinflammation biomarkers, and brain structural and functional alterations
      (using brain fMRI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pathophysiology of delirium is poorly understood; neuroinflammation and brain network
      disruption are claimed as possible causes of delirium.

      The authors want to clarify the role of the alterations of different cellular components of
      neuroinflammation (neurons, glial cells, and endothelium) in delirium development. Moreover,
      the authors want to understand whether the neuroinflammation process could cause permanent
      structural and functional brain damage.

      In a nested cross-sectional longitudinal case-control observational study in ICU admitted
      patients.

      The objectives of the studies are as follow: 1) Neuroinflammation biomarkers evaluation in
      non-neurological ICU patients who develop delirium during ICU-stay (case) compared to matched
      non-delirious ICU patients (control), and 2) their correlation with brain structural and
      functional alterations evaluated with a resting-state fMRI protocol and PET.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">June 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Serum Neuroinflammation biomarkers in patients developing delirium.</measure>
    <time_frame>15 days</time_frame>
    <description>Comparison of neuroinflammation biomarkers in patients developing delirium vs patients who do not develop delirium.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fMRI alteration</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of brain functional alterations during delirium development (evaluated through resting state fMRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between biomarkers alterations and fMRI alterations</measure>
    <time_frame>15 days</time_frame>
    <description>Evaluation of the correlation between serum neuroinflammation biomarkers alteration during delirium development and the alterations noted in during resting state fMRI</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Delirium</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>All patients aspected to stay in ICU for at least 3 days who will develop delirium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>All patients aspected to stay in ICU for at least 3 days who will not develop delirium (1:1 matched with the controls with a propensity score method).</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll 30 critically ill patients in the study (case) matched to 30 controls (see
        sample size calculation).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18

          -  All patients admitted that would be expected to stay in ICU for at least 3 days

        Exclusion Criteria:

          -  Acute neurological condition

          -  Chronic neurological condition (i.e., seizures, stroke, muscular illness).

          -  Hematological malignancy or immunological disease.

          -  Blood transfusion in the last 2 weeks

          -  Ongoing sedation

          -  Any condition which contraindicates MRI execution (presence of non-compatible devices
             or hemodynamic or respiratory instability).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Piva</last_name>
      <phone>+393332564230</phone>
      <phone_ext>+393332564230</phone_ext>
      <email>simone.piva@unibs.it</email>
    </contact>
    <contact_backup>
      <last_name>Fabio Turla</last_name>
      <phone>+393332564230</phone>
      <email>fabioturla2@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 1, 2019</last_update_submitted>
  <last_update_submitted_qc>September 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi di Brescia</investigator_affiliation>
    <investigator_full_name>Piva Simone</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>neuroinflammation</keyword>
  <keyword>fMRI</keyword>
  <keyword>Functional MRI</keyword>
  <keyword>ICU related delirium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The database is in RedCap. We could share all data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Already available</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

